Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials

BACKGROUND: Palbociclib is a small‐molecule, cyclin‐dependent kinase 4 and 6 inhibitor, which prevents phosphorylation of the retinoblastoma (Rb) protein and inhibits cell‐cycle progression from G1 to S phase. We performed this meta‐analysis to estimate the safety and efficacy of palbociclib in canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Linghong, Hu, Yuanyuan, Chen, Xi, Li, Qingfang, Wei, Benling, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488107/
https://www.ncbi.nlm.nih.gov/pubmed/30897298
http://dx.doi.org/10.1002/cam4.1970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488107/
https://www.ncbi.nlm.nih.gov/pubmed/30897298
http://dx.doi.org/10.1002/cam4.1970

Ejemplares similares